Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and other presentations of aged or damaged skin; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx product. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.
Founded in 2015, Krystal Biotech was created with the goal of finding revolutionary solutions for skin diseases using gene therapy.
Our mission is to improve and enhance people's lives by advancing transformative gene technologies to tackle skin diseases.
We envision a world where skin diseases can be cured, not just treated, so that patients can have access to life- changing treatments.
Dr. Andreas C. Orth (Exec. VP & Chief Commercial Officer)
Ms. Gloria Lin (Accounting Mang.)
Mr. Ram Kamineni (Sr. VP of CMC & Technical Operations)
Ms. Meg Dodge (VP of Investor Relations & Corp. Communications)
Mr. David Glynn (Gen. Counsel, Commercial & Compliance)
Mr. John Karakkal (VP of North American Sales & Marketing)
Ms. Katherine Tuminello (HR & Office Mang.)
Recognition and Awards
Krystal Biotech has already been awarded numerous awards including the 2018 Cambridge Global Technology Award, the 2017 Melanoma Research Alliance Award, and the 2016 National Institutes of Health Award.